- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Swissray gets VA contract for AddOn-Multi-System
Swissray gets VA contract for AddOn-Multi-SystemDigital radiography developer Swissray International has received an official contract award from the Department of Veterans Affairs. With the award, Swissray can now actively pursue sales for its
Swissray gets VA contract for AddOn-Multi-System
Digital radiography developer Swissray International has received an official contract award from the Department of Veterans Affairs. With the award, Swissray can now actively pursue sales for its AddOn-Multi-System to VA hospitals, according to New York City-based Swissray. The company values the first year of the contract at $400,000. The VA can extend the contract until March 31, 2001.
The company's Swissray Information Solutions division is also contributing to the company's revenues. The group has provided connectivity products to Dutchess Radiology Associates in Poughkeepsie, NY, and has also provided benchmarking consulting services for an informatics expansion by the DAL Group in Dallas, TX. The two contracts have generated $400,000 in revenue, according to Swissray.
- Search again
- Homepage
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
